Independent Data Safety Monitoring Board Recommends Continuation Of Sangart's Pivotal Phase III Trials Of Hemospan(R) Following Second Interim Review (Lufee.com)

Lufee categories

Independent Data Safety Monitoring Board Recommends Continuation Of Sangart's Pivotal Phase III Trials Of Hemospan(R) Following Second Interim Review
Sangart, Inc., a privately held biopharmaceutical company focused on the research, development and commercialization of oxygen transport agents, announced that an independent data safety monitoring board (DSMB) has recommended the continuation of both Phase III clinical trials of Sangart's lead blood substitute product, Hemospan(R), under current protocols.
- Discuss this news

Tell-a-friend about Lufee and this article

You are not logged in to Lufee at this moment. But you can tell a friend about this headline and send him an e-mail with your personal comment.

You still don't have a Lufee Account?

Sign up now and...

Get your personal account for free and sign up today. The sign up process will take you less than 5 minutes.

Signup here for free

Read what other users has to say

Nobody has posted a comment yet. Be the first to leave feedback on this news.

Read other headlines

New users at Lufee